TCTP promotes glioma cell proliferation in vitro and in vivo via enhanced -catenin/TCF-4 transcription
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background The translationally controlled tumor protein (TCTP) is a multifunctional protein that plays important roles in immune responses, cell proliferation, tumorigenicity and cell apoptosis. Here, we examined the clinical value of TCTP in glioma patient survival and investigated the functional roles and mechanism of TCTP in glioma development. Methods TCTP expression was determined through immunohistochemical staining, immunoblotting, and quantitative real-time PCR (qRT-PCR). TCTP or TCF-4 expression was silenced using short hairpin (sh) RNA. In vitro cell proliferation was detected using MTT, BrdU and colony formation assays, and in vivo tumor growth was performed using the xenograft model. TCTP/TCF-4/β-catenin association was detected using a co-immunoprecipitation (co-IP) assay. TCF-4 transcription activity was detected using a TOPflash/FOPflash report gene assay. Wnt/β-catenin-targeted gene expression was detected through Western blotting. Results TCTP protein levels were significantly elevated in high-grade gliomas compared with low-grade gliomas and normal brain tissues. Importantly, the expression of TCTP was significantly associated with poorer overall survival and disease-free survival, and TCTP also reduced the survival rate after treatment with radiotherapy and temozolomide (RT-TMZ) for glioma patients. The ectopic expression of TCTP enhanced glioma cell proliferation both in vitro and in vivo, whereas the knockdown of TCTP inhibited this effect. Similarly, the overexpression of TCTP increased β-catenin binding to TCF-4, TOPflash report gene transcription activity, and the expression of Wnt/β-catenin signaling target genes including c-Myc and cyclin D1; notably, the knockdown of TCTP reduced these effects. The knockdown of TCF-4 using shRNA rescued the enhanced cell proliferation induced by the overexpression of TCTP. Conclusion TCTP is associated with reduced survival of glioma patients and induces glioma tumor growth through enhanced Wnt/β-catenin signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The translationally controlled tumour protein (TCTP)
Bommer, U.-A., & Thiele, B.-J. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(03)00213-9 · Cited by 447
Cited by
Wnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
“The translationally controlled tumor protein (TCTP) can enhance the transcription complex activity by increasing the ability of β-catenin–Tcf binding and then inducing the growth of glioma tumor.(247) In summary, HOXB13 and RUNX3 are identified as suppressors of Wnt/β-catenin signaling by obstructing Tcf4 activity to…”
BackgroundSelf-citationThe regulation of β-catenin activity and function in cancer: therapeutic opportunities
Shang, S., Hua, F., & Hu, Z.-W. (2017) · Oncotarget · doi:10.18632/oncotarget.15687 · Cited by 641
miR-137: A Novel Therapeutic Target for Human Glioma
Wang, Y., Chen, R., Zhou, X., Guo, R., Yin, J., Li, Y., & Ma, G. (2020) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2020.06.028 · Cited by 40
Self-citationDing, Y., Lv, C., Zhou, Y., Zhang, H., Zhao, L., Xu, Y., & Fan, X. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112666 · Cited by 21
Metadata
- Authors
- Gu, X., Yao, L., Ma, G., Cui, L., Li, Y., Liang, W., Zhao, B., & Li, K.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-12-04
- Volume
- 16
- Issue
- 2
- Pages
- 217-227
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2102175027
- Cited by
- 70
- References
- 1
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.